肿瘤的治疗日新月异,创新药物层出不穷,这极大的提高了肿瘤治疗疗效。其中,程序性死亡蛋白1(PD-1)属于免疫抑制受体,能够通过与其配体程序性死亡配体 1(PD-L1)结合,负性调控 T 细胞的活化、增殖并诱导其凋亡。PD-1/PD-L1信号通路的激活导致肿瘤特异性 T 细胞不能被活化,机体抗肿瘤免疫应答受到抑制,从而使肿瘤细胞逃避机体的免疫监视和杀伤。因此,通过药物阻断该通路则能够显著增强抗肿瘤免疫功能,促进有效和持久的宿主肿瘤免疫力的发生,从而抑制肿瘤的进一步发展。由于宫颈癌多数与HPV感染密切相关,导致PD-L1表达增加,因此免疫检查点抑制剂在宫颈癌治疗中具有较大的潜力。
[1] Monk BJ, Enomoto T, Kast WM, et al. Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials[J]. Cancer Treat Rev . 2022 Mar 31;106:102385.
[2] SANTIN A D, DENG W, FRUMOVITZ M, et al. Phase Ⅱ evalu_x0002_ation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)[J]. Gynecol Oncol. 2020;157(1):161-166.
[3] Positive Phase 3 Libtayo® (cemiplimab) Results in Advanced Cervical Cancer Presented at ESMO Virtual Plenary. News release. Regeneron Pharmaceuticals, Inc. and Sanofi. May 12, 2021.
[4] 10.1136/ijgc-2021-IGCS.14
[5] Chung H C, Ros W, Delord J P, et al. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study[J]. Journal of Clinical Oncology, 2019.
[6] Song Y, et al. 2021 ASCO Abstract 7529.
[7] Song Y, et al. Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study[J] Leukemia.2020;34(2):533-542.
[8] Shi Y, Su H, Song Y, et al. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial[J]. Lancet Haematol.2019;6(1):e12-e19.
[9] Song Y, et al. A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma[J].Clin Cancer Res. 2019 Dec 15;25(24):7363-7369.
[10] Chen R, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087[J].Blood. 2019 Oct 3;134(14):1144-1153.
[11] Armand P, et al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial[J]. J Clin Oncol. 2018 May 10;36(14):1428-1439.